<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03721965</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 39110-120</org_study_id>
    <nct_id>NCT03721965</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects</brief_title>
  <official_title>An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Itacitinib in Combination With Corticosteroids for the Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Pediatric Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate itacitinib in combination with corticosteroids for
      the treatment of Grades II to IV acute graft-versus-host disease (aGVHD) in steroid-naive
      pediatric participants.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated due to lack of efficacy in a separate phase III study
  </why_stopped>
  <start_date type="Actual">April 16, 2019</start_date>
  <completion_date type="Actual">February 17, 2020</completion_date>
  <primary_completion_date type="Actual">February 17, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Participants with treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>Safety and tolerability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: Cmax of itacitinib when administered with corticosteroids</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Maximum observed plasma concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: Cmin of itacitinib when administered with corticosteroids</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Minimum observed plasma concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: Tmax of itacitinib when administered with corticosteroids</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Time to maximum concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: AUC of itacitinib when administered with corticosteroids</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Area under the plasma concentration-time curve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: Cl/F of itacitinib when administered with corticosteroids</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Apparent oral dose clearance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Overall response rate</measure>
    <time_frame>Day 28</time_frame>
    <description>Defined as the proportion of participants demonstrating a complete response (CR), very good partial response (VGPR), or partial response (PR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Overall response rate</measure>
    <time_frame>Day 28</time_frame>
    <description>Defined as the proportion of participants demonstrating a CR, VGPR, or PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Cmax of itacitinib when administered with corticosteroids</measure>
    <time_frame>Day 7</time_frame>
    <description>Maximum observed plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Cmin of itacitinib when administered with corticosteroids</measure>
    <time_frame>Day 7</time_frame>
    <description>Minimum observed plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Tmax of itacitinib when administered with corticosteroids</measure>
    <time_frame>Day 7</time_frame>
    <description>Time to maximum concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: AUC of itacitinib when administered with corticosteroids</measure>
    <time_frame>Day 7</time_frame>
    <description>Area under the plasma concentration-time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Cl/F of itacitinib when administered with corticosteroids</measure>
    <time_frame>Day 7</time_frame>
    <description>Apparent oral dose clearance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Overall response rate</measure>
    <time_frame>Up to 100 days</time_frame>
    <description>Defined as the proportion of participants demonstrating a CR, VGPR, or PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Nonrelapse mortality</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Defined as the proportion of participants who died due to causes other than underlying hematologic disorders relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Duration of response</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>Defined as the time of the onset of response to loss of response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Time to response</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>Defined as the interval from treatment initiation to first response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Relapse rate of malignant and nonmalignant disorders</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>Defined as the proportion of participants whose underlying disease relapses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Malignant and nonmalignant disorders relapse-related mortality rate</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>Defined as the proportion of participants whose underlying hematologic disorder relapses and has a fatal outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Failure-free survival</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Defined as the proportion of participants who are still alive, have not relapsed, have not required additional therapy for aGVHD, and have not demonstrated signs or symptoms of chronic GVHD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Overall survival</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>Defined as the interval from study enrollment to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Number of adverse events</measure>
    <time_frame>Up to approximately 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Incidence rate of secondary graft failure</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>To assess the proportion of participants experiencing secondary graft failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Average corticosteroid dose</measure>
    <time_frame>Up to 180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Cumulative corticosteroid dose</measure>
    <time_frame>Up to 180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Proportion of participants who discontinue corticosteroids</measure>
    <time_frame>Up to 100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Proportion of participants who discontinue immunosuppressive medication</measure>
    <time_frame>Up to 100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Incidence rate of aGVHD flares</measure>
    <time_frame>Day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Incidence rate of cGVHD</measure>
    <time_frame>Up to 365 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Acute Graft-versus-host Disease</condition>
  <arm_group>
    <arm_group_label>Itacitinib + Corticosteroids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itacitinib</intervention_name>
    <description>Phase 1: Itacitinib administered orally once daily at the protocol-defined dose according to age cohort, with dose reductions or modifications based on safety assessments. Phase 2: Itacitinib administered orally once daily at the recommended dose from Phase 1.</description>
    <arm_group_label>Itacitinib + Corticosteroids</arm_group_label>
    <other_name>INCB039110</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroids</intervention_name>
    <description>Phase 1 and 2: Methylprednisolone 2 mg/kg IV daily (or prednisone equivalent) or at a dose that is appropriate for the severity of disease as outlined per local treatment guidelines as background treatment.</description>
    <arm_group_label>Itacitinib + Corticosteroids</arm_group_label>
    <other_name>prednisone, methylprednisolone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female participants: 12 to &lt; 18 years old (Cohort 1), 6 to &lt; 12 years old
             (Cohort 2), 2 to &lt; 6 years old (Cohort 3), Weighing &gt; 8 kg to &lt; 2 years old (Cohort
             4), and 28 days old to weighing ≤ 8 kg (Cohort 5).

          -  Undergone 1 allogeneic hematopoietic stem cell transplantation (allo-HSCT) from any
             donor and source for hematological malignancies or disorders. Recipients of
             myeloablative and reduced-intensity conditioning regimens are eligible.

          -  Clinically suspected Grade II to IV aGVHD as per Mount Sinai Acute GVHD International
             Consortium (MAGIC) criteria, occurring after allo-HSCT and any GVHD prophylactic
             medication.

          -  Evidence of myeloid engraftment.

        Exclusion Criteria:

          -  More than 1 allo-HSCT.

          -  Received more than 2 days of systemic corticosteroids for aGVHD before the first study
             drug administration.

          -  Presence of GVHD overlap syndrome.

          -  Presence of an active uncontrolled infection.

          -  Known HIV infection.

          -  Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection that requires
             treatment or at risk for HBV reactivation.

          -  Evidence of relapsed primary disease or have been treated for relapse after the
             allo-HSCT was performed.

          -  Any corticosteroid therapy for indications other than GVHD at doses &gt; 1 mg/kg once
             daily of methylprednisolone (or equivalent) within 7 days of the first study drug
             administration.

          -  Receipt of live (including attenuated) vaccines or anticipation of need for such
             vaccines during the study.

          -  Receipt of JAK inhibitor therapy after allo-HSCT for any indication.

          -  Treatment with any other investigational agent, device, or procedure within 21 days
             (or 5 half-lives, whichever is greater) of enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodica Morariu-Zamfir, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado - Center for Cancer and Blood Disorders</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours/A.I. duPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nicklaus Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center - Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doernbecher Children's Hospital - Division of Pediatric Hematology</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia - Center for Childhood Cancer Research</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute, LLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Rennes</name>
      <address>
        <city>Rennes</city>
        <state>Cedex 2</state>
        <zip>35203</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires De Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <state>Cedex</state>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38403</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Debre Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires De Strasbourg</name>
      <address>
        <city>Strasbourg Cedex</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nancy</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Aachen, AoeR</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Jena, Klinik fur Kinder und Jugendmedizin</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Unversitatia Policlinico - Vittorio Emanuele - Presido Ospedaliero G. Rodolico</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione MBBM</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesu</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Citta della Salute e della Scienza di Torino - Ospedale Regina Margherita</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall D Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico de Santiago de Compostela</name>
      <address>
        <city>Santiago De Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Childrens Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Hospital for Children</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust</name>
      <address>
        <city>Leeds</city>
        <zip>LS13EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Manchester University Hospital - Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital - Surrey</name>
      <address>
        <city>Surrey Quays</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 25, 2018</study_first_submitted>
  <study_first_submitted_qc>October 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2018</study_first_posted>
  <last_update_submitted>March 12, 2020</last_update_submitted>
  <last_update_submitted_qc>March 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute graft-versus-host disease</keyword>
  <keyword>GVHD</keyword>
  <keyword>pediatric</keyword>
  <keyword>JAK1 inhibitor</keyword>
  <keyword>corticosteroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

